Objective: To analyze the cases diagnosed as myeloid sarcoma on fine-needle aspiration cytology (FNAC) of lymph nodes. Study Design: Ten cases of lymph node aspirate diagnosed as myeloid sarcoma were analyzed. FNAC was performed as a routine outpatient procedure in all cases. Correlation with peripheral smear, bone marrow examination, flow cytometry and cytogenetics was done wherever possible. Results: Diagnosis of a hematologic malignancy, before fine-needle aspiration, was available in only 2 cases. All 10 cases showed eosinophilic precursors while five aspirates showed megakaryocytes with dysplastic forms. Of the 10 cases, 3 were diagnosed as acute myeloid leukemia, 3 as chronic myeloid leukemia, 1 case as juvenile myelomonocytic leukemia, 1 case proved to be precursor T acute lymphoblastic leukemia/lymphoma and 2 patients did not show blasts on peripheral blood smear but showed blasts, dysplastic megakaryocytes and eosinophilic precursors in the aspirate. Conclusion: Thorough workup to search for an underlying hematological malignancy should be done whenever dysplastic megakaryocytes and/or eosinophilic precursors are seen in lymph node aspirate.

Brunning RD, Matutes E, Harris NL, et al: Acute myeloid leukaemia: introduction; in Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyons, IARC 2001, pp 77–80.
Meis JM, Butler JJ, Osborne BM, et al: Granulocytic sarcoma in nonleukemic patients. Cancer 1986;58:2697–2709.
Elenitoba-Johnson K, Hodges GF, King TC, et al: Extramedullary myeloid cell tumors arising in the setting of chronic myelomonocytic leukemia. A report of two cases. Arch Pathol Lab Med 1996;120:62–67.
List AF, Gonzalez-Osete G, Kummet T, et al: Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. Am J Med 1991;90:274–276.
Muss HB, Moloney WC: Chloroma and other myeloblastic tumors. Blood 1973;42:721–728.
Breccia M, Mandelli F, Petti MC, et al: Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res 2004;28:1165–1169.
Tsimberidou AM, Kantarjian HM, Estey E, et al: Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 2003;17:1100–1103.
List AF, Gonzalez-Osete G, Kummet T, et al: Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. Am J Med 1991;90:274–276.
O’Malley DP: Benign extramedullary myeloid proliferations. Mod Pathol 2007;20:405–415.
Byrd JC, Edenfield WJ, Shields DJ, et al: Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995;13:1800–1816.
Cross AH, Goorha RM, Nuss R, et al: Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity. Blood 1988;72:579–587.
Metzgeroth G, Walz C, Score J, et al: Recurrent finding of FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T cell lymphoma. Leukemia 2007;21:1183–1188.
Ioachim HL, Medeiros LJ: Lymphoblastic leukemia/lymphoma; in: Ioachim’s Lymph Node Pathology, ed 4. Philadelphia, Lippincott Williams & Wilkins, 2004, pp 333–351.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.